xi's moments
Home | Europe

CureVac fails in COVID-19 vaccine trial with 47% efficacy

By Ouyang Xueyan | chinadaily.com.cn | Updated: 2021-06-18 00:04

German biotech CureVac's COVID-19 vaccine has come out of a late-stage trial with 47 percent efficacy but the health ministry has said this will not impact the country's vaccination rollout.

Global Edition
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349